Cell adhesion inhibitors

Details Cell adhesion inhibitors Cell adhesion inhibitors

2007-03-27

2007-03-27

Wilson, James O. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S423000, C548S519000, C548S537000

Reexamination Certificate

active

10892400

ABSTRACT:
Cell adhesion inhibitors can interact with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. An inhibitor including a polyethylene glycol moiety can have advantageous pharmaceutical properties.

REFERENCES:
patent: 4725583 (1988-02-01), Luly et al.
patent: 4826815 (1989-05-01), Luly et al.
patent: 4908360 (1990-03-01), Martin et al.
patent: 5260277 (1993-11-01), McKenzie
patent: 5314902 (1994-05-01), Tjoeng et al.
patent: 5399570 (1995-03-01), Klingler et al.
patent: 5403836 (1995-04-01), Blackburn et al.
patent: 5434188 (1995-07-01), Boschelli et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5922755 (1999-07-01), Tanaka et al.
patent: 6630503 (2003-10-01), Scott et al.
patent: 2002/0015999 (2002-10-01), Mundy et al.
patent: 2002/0159998 (2002-10-01), Mundy et al.
patent: 0 021 234 (1981-01-01), None
patent: 0 460 679 (1991-12-01), None
patent: 0 357 192 (1992-05-01), None
patent: 0 519 748 (1992-12-01), None
patent: WO 89/09786 (1989-10-01), None
patent: WO 91/02750 (1991-03-01), None
patent: WO 91/09837 (1991-07-01), None
patent: WO 92/00995 (1992-01-01), None
patent: WO 92/08464 (1992-05-01), None
patent: WO 92/22323 (1992-12-01), None
patent: WO 93/08823 (1993-05-01), None
patent: WO 93/09795 (1993-05-01), None
patent: WO 93/12809 (1993-07-01), None
patent: WO 94/02445 (1994-02-01), None
patent: WO 94/15958 (1994-07-01), None
patent: WO 95/15973 (1995-06-01), None
patent: WO 96/22966 (1996-08-01), None
patent: WO 97/03094 (1997-01-01), None
patent: WO 98/04913 (1998-02-01), None
patent: WO98/53814 (1998-12-01), None
patent: WO98/53817 (1998-12-01), None
patent: WO98/53818 (1998-12-01), None
patent: WO99/06432 (1999-02-01), None
patent: WO 99/06433 (1999-02-01), None
patent: WO99/06434 (1999-02-01), None
patent: WO99/10312 (1999-03-01), None
patent: WO 99/26921 (1999-06-01), None
patent: WO99/26922 (1999-06-01), None
patent: WO99/26923 (1999-06-01), None
patent: WO 99/61421 (1999-12-01), None
patent: WO 00/47564 (2000-08-01), None
Theien, et al., Blood, vol. 102(13), pp. 4464-4471 (2003).
Leone, et al., J. of Pharmacology and Experimental Therapeutics, vol. 305(3), pp. 1150-1162 (2003).
Egger, et al., J. of Pharmacology and Experimental Therapeutics, vol. 306(3), pp. 903-913(2003).
Abraham et al., “α4-Integrins Mediate Antigen-induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in sheep”, J Clin. Invest., vol. 93, pp. 776-787, (1994).
Bajusz et al., “Design and Synthesis of Peptide Inhibitors of Blood Coagulation”, Folia Haematol., Leipzig, vol. 109, pp. 16-21, (1982).
Baldwin et al., “An Efficient Substitute for the α-aminoadipoyl Moiety of λ-(L-α-amimoadipoyl)-L-cysteinyl-D-valine in the Enzymatic Synthesis of Penicillins”, Tetrahedron, vol. 43, No. 18, pp. 4217-4220, (1987).
Chen et al., “Facile synthesis of N-protected peptide fragments using polymer-bound 1-hydroxybenzotriazole as an active ester”, Chemical Abstracts, vol. 115, p. 1003, 115:159756r (1991).
Chisholm et al., “Monoclonal antibodies to the integrin α-4 subunit inhibit the murine contact hypersensitivity response”, European Journal of Immunology, vol. 23, pp. 682-688, (1993).
Elices et al., “Expression and Functional Significance of Alternatively Spliced CSI Fibronectin in Rheumatoid Arthritis Microvasculature”, The Journal of Clinical Investigation, vol. 93, pp. 405-416, (1994).
Ferguson et al. “Antigen-Independent Processes in Antigen-Specific Immunity”, The Journal of Immunology, vol. 150, No. 4, pp. 1172-1182, (1993).
Ferguson et al., “Two integrin-binding peptides abrogate T cell-mediated immune responsesin vivo”, Proceedings of the National Academy of Sciences USA, vol. 88, pp. 8072-8076, (1991).
Goodman et al., “Synthesis and Conformation of Sequential Polypeptides of L-Alanine and beta-Aminobutyric Acid”, Macromolecules, vol. 9, No. 1, pp. 1-6, (1976).
Greenstein et al., “Chemistry of the Amino Acids,” John Wiley and Sons, Inc., vol. 2, pp. 1162-1186.
Gruszecki et al., “Diacylamine-perfekte Acylierungsmittel fur die Peptidsynthese”, Liebigs Ann. Chem., pp. 331-336, (1988).
Hemler, “VLA Proteins in the Integrin Family: Structures. Functions. and Their Role on Leukocytes”, Annual Review of Immunology, vol. 8, pp. 365-400, (1990).
Jiang et al., “Approaches Toward the Total Synthesis of Astins A, B, And C”, Tetrahedron Letters, vol. 35, No. 14, pp. 2121-2124, (1994).
Kim et al., “Inhibition of125I-Labeled Ristocetin Binding toMicrococcus luteusCells by the Peptides Related to Bacterial Cell Wall Mucopeptide Precursors: Quantitative Structure-Activity Relationships”, Journal of Medical Chemistry, vol. 32, No. 1, pp. 84-93, (1989).
Komoriya et al., “The Minimal Essential Sequence for a Major Cell Type-specific Adhesion site (CSI) within the Alternatively Spliced . . . ”, Journal of Biological Chemistry, vol. 266, No. 23, pp. 15075-15079, (1991).
Lampi, et al., “Comparison of Cell-Permeable Calpain Inhibitors and E64 in Reduction of Cataract in Cultured Rat Lenses”, Toxicology and Applied Pharmacology, vol. 117, pp. 53-57, (1992).
Lin, Ko-Chung, et al., “Selective, Tight Binding Inhibitors of Integrin α4β1 That Inhibit Allergic Airway Responses”, Journal of Medicinal Chemistry, vol. 42, No. 5, pp. 920-934, (1999).
Lobb et al., “The Pathophysiologic Role of α4 Integrins in Vivo”, The Journal of Clinical Investigation, vol. 94, pp. 1722-1728, (1994).
Melmon et al., “III Drug Interactions”, The Pharmacological Basis of Therapeutics, 6thEdition, MacMillan Publishing Co., Inc. © 1980, pp. 1738-1740.
Molossi et al., “Blockade of Very Late Antigen-4 Integrin binding to Fibronectin with Connecting Segment-1 Peptide Reduces Accelerated Coronary Arteriopathy . . . ”, Journal of Clinical Investigation, vol. 95, pp. 2601-2610, (1995).
Morales-Ducret et al., “α4/ β1 INTEGRIN (VLA-4) Ligands In Arthritis Vascular Cell Adhesion Molecule-1 Expression in Synovium and on . . . ”, The Journal of Immunology, vol. 149, No. 4, pp. 1424-1431, (1992).
Narumiya et al., “Pre-B cells adhere to fibronectin via interactions of integrin α5/αv with RGDS as well as of integrin α4 with two distinct V region sequences at its different biding sites”, Intl. Immun., vol. 6, No. 1, pp. 139-147, (1994).
Nowlin et al., “A Novel Cyclic Pentapeptide Inhibits α4β1 Integrin-mediated Cell Adhesion”, The Journal of Biological Chemistry, vol. 25, No. 27, pp. 20352-20359, (1993).
Sawyer, T. K., “Peptidomimetic Design and Chemical Approaches to Peptide Metabolism”, Peptide-Based Drug Design: controlling transport and metabolism © 1995, ACS Professional Reference Book, pp. 387-442.
Subasinghe et al., “Synthesis of Acyclic and Dehydroaspartic Acid Analogues of Ac-Asp-Glu-OH and Their Inhibition of Rat Brain N-Acetylated α-Linked Acidic Dipeptidase (NAALA Dipeptidase)”, Journal of Medicinal Chemistry, vol. 33, No. 10, pp. 2734-2744, (1990).
Thierry et al., “Synthesis and Activity of NAcSerAspLysPro Analogues on Cellular Interactions between T-Cell and Erythrocytes in Rosette Formation,” Jouranl of Medical Chemistry, vol. 33, pp. 2122-2127, (1990).
Wayner et al., “Activation-dependent Recognition by Hematopoietic Cells of the LDV Sequence in the V Region of Fibronectin”, The Journal of Cell Biology, vol. 16, No. 2, pp. 489-497, (1992).
Yednock et al., “Prevention of experimental autoimmune encephalomyelitis by antibodies against α4 β1 integrin”, Nature, vol. 356, pp. 63-66, (1992).
Zimmerman, Craig N., “Peptide and peptodomimetic inhibitors of VLA-4”, Expert Opinion of Therapeutic Patents, Ashley Publication, GB, vol. 9, No. 2, pp. 129-133, (1999).

Affiliated with

Also associated with

Rating

Cell adhesion inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cell adhesion inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell adhesion inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3754703